Target Name: MIR618
NCBI ID: G693203
Review Report on MIR618 Target / Biomarker Content of Review Report on MIR618 Target / Biomarker
MIR618
Other Name(s): hsa-miR-618 | mir-618 | microRNA 618 | MIRN618 | MicroRNA 618 | hsa-mir-618

Unlocking The Potential of MIR618: A Non-Coding RNA Molecule as A Drug Target and Biomarker

MIR618, also known as hsa-miR-618, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to study, and its potential as a drug have piqued the interest of pharmaceutical companies.

MIR618 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. It is expressed in a variety of tissues and cells and is involved in the regulation of various biological processes, including cell growth, apoptosis, and inflammation.

One of the reasons MIR618 has generated so much interest is its unique structure. MIR618 is a double-stranded RNA molecule that has a length of approximately 24 amino acids. It has a highly conserved secondary structure, with a stem-loop and a loop region in the middle. The stem-loop region is composed of three conserved amino acids that are involved in the formation of a positive hairpin loop, while the loop region is composed of three conserved amino acids that form a negative hairpin loop.

MIR618 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. During apoptosis, MIR618 has been shown to interact with the protein Bcl-2, which is a transcription factor that can promote cell survival. By binding to Bcl-2, MIR618 can inhibit its activity and promote cell apoptosis. This has led to the speculation that MIR618 may be a potential drug target for cancer.

Another potential mechanism by which MIR618 may be involved in cancer is its role in the regulation of cell proliferation. MIR618 has been shown to play a role in the regulation of cell cycle progression, with studies showing that it can inhibit the activity of the protein kinase AT kinase (ATK) and prevent cell proliferation. This has led to the hypothesis that MIR618 may be a potential drug target for cancer.

MIR618 has also been shown to be involved in the regulation of inflammation. Studies have shown that MIR618 can modulate the expression of genes involved in inflammation, including the production of pro-inflammatory cytokines. This has led to the hypothesis that MIR618 may be a potential drug target for treating inflammatory disorders.

In addition to its potential as a drug target, MIR618 also has potential as a biomarker. Its unique expression patterns have made it an attractive target for study, with studies showing that MIR618 is expressed in a variety of tissues and cells and can be used as a reliable biomarker for certain diseases. For example, MIR618 has been shown to be expressed in various types of cancer, including breast, lung, and colon cancer. This suggests that it may be a useful biomarker for these diseases.

Furthermore, MIR618 has also been shown to have potential as a diagnostic tool. Its unique structure and expression patterns have made it an attractive target for study, with studies showing that it can be used to predict the outcomes of certain diseases. For example, MIR618 has been shown to be expressed in the blood samples of patients with heart disease, and studies have shown that it can be used to predict the outcomes of patients with certain types of cancer. This suggests that it may be a useful diagnostic tool for these diseases.

In conclusion, MIR618 is a unique and fascinating molecule that has generated a lot of interest in recent years. Its unique structure and expression patterns have made it an attractive target for study, and its potential as a drug target and biomarker has piqued the interest of pharmaceutical companies. Further research is needed to fully understand the role of MIR618 in

Protein Name: MicroRNA 618

The "MIR618 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR618 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR619 | MIR620 | MIR621 | MIR622 | MIR623 | MIR624 | MIR625 | MIR626 | MIR627 | MIR628 | MIR629 | MIR630 | MIR631 | MIR632 | MIR633 | MIR634 | MIR635 | MIR636 | MIR637 | MIR638 | MIR639 | MIR640 | MIR641 | MIR642A | MIR642B | MIR643 | MIR644A | MIR645 | MIR646 | MIR646HG | MIR647 | MIR648 | MIR649 | MIR6499 | MIR650 | MIR6500 | MIR6501 | MIR6502 | MIR6503 | MIR6504 | MIR6505 | MIR6506 | MIR6507 | MIR6508 | MIR6509 | MIR651 | MIR6510 | MIR6511A1 | MIR6511A2 | MIR6511A3 | MIR6511A4 | MIR6511B1 | MIR6511B2 | MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737